Baidu
map
PHARM DEV TECHNOL 润色咨询

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

出版年份：1996 年文章数：1171 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：11.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2024-01-10 ms2000001469312267

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：药学
    经验分享：才投，不知道怎么样

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2021-12-29 MS68862005

    选择期刊时应该注意什么？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    除文章内容和质量外，选刊时还需注意什么？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2018-01-05 Yy314128

    审稿速度:6.0
    经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2017-11-06 1e1b4286m89(暂无匿称)

    审稿速度:1.0
    经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2017-01-16 红博士2016

    Pharmaceutical Development and Technology
    该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2016-04-01 witcui

    投稿1天后被拒

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2013-09-09 ms8780191241558819

    主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2013-09-02 ms7999216884373889

    请问审稿费和版面费多少啊？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2180468, encodeId=28de218046834, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：药学<br>经验分享：才投，不知道怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d46153287, createdName=ms2000001469312267, createdTime=Wed Jan 10 11:40:26 CST 2024, time=2024-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096959, encodeId=c06c109695962, content=选择期刊时应该注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1096960, encodeId=db1310969602b, content=除文章内容和质量外，选刊时还需注意什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550676, encodeId=8abc5506e6de, content=审稿速度:6.0<br>经验分享：投稿至今4个月，一直under review。写了催稿信也没有回复。我能怎么办，我也很绝望啊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=406, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c61727169, createdName=Yy314128, createdTime=Fri Jan 05 10:16:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548936, encodeId=6312548936f5, content=审稿速度:1.0<br>经验分享：研究肿瘤转移的投了这个，12小时内被拒了，效率真高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=389, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJt9eFezfhFo6b2ByicaxLRE5Z7BAcZ6x4YyPLxaJsPB8LxIsQtick9yicTEE7dqbOCic92oxsgdw6SAw/132, createdBy=90901995107, createdName=1e1b4286m89(暂无匿称), createdTime=Mon Nov 06 10:02:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531921, encodeId=22655319216c, content=Pharmaceutical Development and Technology <br> 该期刊的网址打不开啊？谁有好用的？麻烦给一个，谢谢啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f1727865, createdName=红博士2016, createdTime=Mon Jan 16 10:53:00 CST 2017, time=2017-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=520944, encodeId=5b0c520944d4, content=投稿1天后被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=375, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfba104678, createdName=witcui, createdTime=Fri Apr 01 14:51:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827992, encodeId=83a182e992ad, content=主编很好，3月份投稿，4月给了初审意见，后面各种小曲折，有些插曲，二修后10天被接收即6月份，审稿人意见很中肯！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bff55414034, createdName=ms8780191241558819, createdTime=Mon Sep 09 16:57:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=827855, encodeId=11ee82e855ec, content=请问审稿费和版面费多少啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a75413984, createdName=ms7999216884373889, createdTime=Mon Sep 02 23:24:00 CST 2013, time=2013-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=819999, encodeId=4f408199998d, content=投稿20天左右给回复，主编很友善！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df4c5413960, createdName=ms8480212230682571, createdTime=Thu Jun 14 09:02:00 CST 2012, time=2012-06-14, status=1, ipAttribution=)]
    2012-06-14 ms8480212230682571

    投稿20天左右给回复，主编很友善！

    0

共14条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map